Uses mass spectrometry-based quantitative proteomics to analyze the proteome in acute myeloid leukemia (AML) patient cells, aiming to unravel more of the complex biological processes behind AML and to find prognostic biomarkers which can guide therapeutic decisions.
Other research interests are cell-cell communication in the AML microenviroment and proteomic method optimization.
- (2017). Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
- (2016). Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
- (2016). Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
- (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
- (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
- (2014). Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
- (2014). Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
- (2019). An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia. Current Medicinal Chemistry. 5293-5316.
- (2018). Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. Expert Review of Hematology. 13-24.
- (2017). Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opinion on Drug Discovery. 1053-1065.
Acute myeloid leukemia research